Free Trial
NASDAQ:ASPI

ASP Isotopes Q3 2023 Earnings Report

ASP Isotopes logo
$7.59 +0.60 (+8.58%)
As of 12:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ASP Isotopes EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ASP Isotopes Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ASP Isotopes Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Earnings Documents

ASP Isotopes Earnings Headlines

Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. With gold at record highs and Bridgewater now buying in, one analyst believes Buffett’s next move could hit by August 15th. He’s identified the gold miner that fits Buffett’s profile — plus four smaller plays with even more upside.
See More ASP Isotopes Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ASP Isotopes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ASP Isotopes and other key companies, straight to your email.

About ASP Isotopes

ASP Isotopes (NASDAQ:ASPI), Inc. (NASDAQ: ASPI) is a specialty materials company focused on the production, purification and distribution of both stable and radioactive isotopes. The company’s core offerings include high-purity isotopic materials for use in nuclear medicine, radiopharmaceutical development, advanced research and industrial applications. With proprietary separation and purification technologies, ASP Isotopes delivers customizable solutions that meet stringent regulatory and quality standards demanded by biotechnology firms, hospitals and government research facilities.

Founded in 2021 and headquartered in Germantown, Maryland, ASP Isotopes operates an integrated manufacturing network that spans isotope extraction, chemical conversion and final packaging. The company’s vertically integrated model allows for enhanced traceability and process control at every stage of production, from raw material procurement through refined isotope delivery. This integration not only streamlines lead times but also supports the development of niche isotopic species and tailored formulations that are critical to emerging therapies and diagnostic imaging protocols.

ASP Isotopes’ global footprint includes distribution centers and partnerships across North America, Europe and Asia, ensuring reliable supply chains for customers worldwide. The firm collaborates with premier academic institutions and national laboratories to advance isotope research and accelerate the transfer of novel radiopharmaceuticals to clinical trials. In parallel, ASP Isotopes engages in strategic alliances with industrial OEMs to supply isotopes used in electronics manufacturing, environmental monitoring and non‐destructive testing applications.

Under the leadership of President and CEO Dr. Emily Richards, a seasoned executive with over two decades of experience in radiochemical manufacturing and regulatory affairs, ASP Isotopes has prioritized quality assurance and regulatory compliance. The company’s management team combines expertise in chemical engineering, nuclear physics and pharmaceutical development, positioning ASP Isotopes to capitalize on growing demand for specialized isotopes. As the medical and industrial sectors continue to expand their reliance on isotopic technologies, ASP Isotopes aims to reinforce its role as a trusted supplier while pursuing incremental capacity expansions and advancements in separation techniques.

View ASP Isotopes Profile

More Earnings Resources from MarketBeat